Results 21 to 30 of about 46,962 (257)

Safe discontinuation of nilotinib in a patient with chronic myeloid leukemia: a case report [PDF]

, 2014
Case presentation. We report the case of a 64-year-old Caucasian man diagnosed with chronic-phase chronic myeloid leukemia in April 2005. After 4 years of treatment with imatinib, he became intolerant to the drug and was switched to nilotinib.
CAOCCI, GIOVANNI, Greco M, LA NASA, GIORGIO   +2 more
core   +2 more sources

Dasatinib inhibits actin fiber reorganization and promotes endothelial cell permeability through RhoA‐ROCK pathway

Cancer Medicine, 2017
Treatment with dasatinib, a tyrosine kinase inhibitor, is associated with edema, pleural effusion, and pulmonary edema. We investigated the effect of dasatinib on the barrier function of human microvascular endothelial cells‐1 (HMEC‐1) in vitro and in ...
Swapan K. Dasgupta, Anhquyen Le, K. Vinod Vijayan, Perumal Thiagarajan   +3 more
doaj   +1 more source

Rho-Kinase Inhibition Ameliorates Dasatinib-Induced Endothelial Dysfunction and Pulmonary Hypertension

Frontiers in Physiology, 2018
The multi-kinase inhibitor dasatinib is used for treatment of imatinib-resistant chronic myeloid leukemia, but is prone to induce microvascular dysfunction.
Csilla Fazakas, Csilla Fazakas, Chandran Nagaraj, Diana Zabini, Attila G. Végh, Leigh M. Marsh, Imola Wilhelm, István A. Krizbai, Horst Olschewski, Andrea Olschewski, Zoltán Bálint, Zoltán Bálint   +11 more
doaj   +1 more source

Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients [PDF]

, 2018
open25noSecond-generation tyrosine kinase inhibitors (2G-TKIs) dasatinib and nilotinib produced historical rates of about 50% complete cytogenetic response (CCyR) and about 40% major molecular response (MMR) in chronic myeloid leukaemia (CML) patients ...

core   +1 more source

Retracted: Dasatinib promotes TRAIL‐mediated apoptosis by upregulating CHOP‐dependent death receptor 5 in gastric cancer

FEBS Open Bio, 2018
Dasatinib, a tyrosine kinase inhibitor, has been approved for first‐line treatment of leukemia and has also been evaluated for use in numerous other cancers. However, its role in gastric cancer (GC) remains unclear.
Xiaona Wang, Qiang Xue, Liangliang Wu, Baogui Wang, Han Liang   +4 more
doaj   +1 more source

Preferential antitumor effect of the Src inhibitor dasatinib associated with a decreased proportion of aldehyde dehydrogenase 1-positive cells in breast cancer cells of the basal B subtype

BMC Cancer, 2010
Background Recent studies have suggested that the Src inhibitor dasatinib preferentially inhibits the growth of breast cancer cells of the basal-like subtype.
Watanabe Mika, Kozuka Yuji, Moriya Takuya, Kanomata Naoki, Kurebayashi Junichi, Sonoo Hiroshi   +5 more
doaj   +1 more source

Change of right ventricular systolic pressure can indicate dasatinib‐induced pulmonary arterial hypertension in chronic myeloid leukemia

Cancer Medicine, 2021
Background We investigated the feasibility of the clinical application of non‐invasive transthoracic echocardiography for diagnosis of pulmonary arterial hypertension induced by dasatinib (D‐PAH) in chronic myeloid leukemia (CML).
Sung‐Eun Lee, Jee Hyun Kong, Soo‐Hyun Kim, Eun‐Jung Jang, Nack‐Gyun Chung, Bin Cho, Suk Joong Oh, Hae‐Eok Jung, Ho‐Joong Youn, Woo‐Baek Chung, Dong‐Wook Kim   +10 more
doaj   +1 more source

Treatment Effects of the Second-Generation Tyrosine Kinase Inhibitor Dasatinib on Autoimmune Arthritis

Frontiers in Immunology, 2019
Rheumatoid arthritis (RA) is a multifactorial autoimmune disease that primarily manifests as persistent synovitis and progressive joint destruction.
Kai Guo, Kai Guo, Xin Bu, Chongfei Yang, Xiaorui Cao, Huan Bian, Qingsheng Zhu, Jinyu Zhu, Dawei Zhang   +8 more
doaj   +1 more source

Dasatinib accelerates valproic acid-induced acute myeloid leukemia cell death by regulation of differentiation capacity. [PDF]

PLoS ONE, 2014
Dasatinib is a compound developed for chronic myeloid leukemia as a multi-targeted kinase inhibitor against wild-type BCR-ABL and SRC family kinases. Valproic acid (VPA) is an anti-epileptic drug that also acts as a class I histone deacetylase inhibitor.
Sook-Kyoung Heo, Eui-Kyu Noh, Dong-Joon Yoon, Jae-Cheol Jo, Jae-Hoo Park, Hawk Kim   +5 more
doaj   +1 more source

Post-treatment de-phosphorylation of p53 correlates with dasatinib responsiveness in malignant melanoma

BMC Cell Biology, 2018
Background Dasatinib (Sprycel) was developed as a tyrosine kinase inhibitor targeting Bcr-Abl and the family of Src kinases. Dasatinib is commonly used for the treatment of acute lymphoblastic and chronic myelogenous leukemia.
Josip Skoko, Jan Rožanc, Emilie M. Charles, Leonidas G. Alexopoulos, Markus Rehm   +4 more
doaj   +1 more source